Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology 2013 Annual Meeting

Response Genetics, Inc. Announces Presentations at the American Society of
Clinical Oncology 2013 Annual Meeting

LOS ANGELES, May 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that abstracts will be presented at the upcoming American
Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL May 31 to
June 4, 2013. The abstracts demonstrate the clinical utility of Response
Genetics' proprietary ResponseDX® ERCC1 gene expression test in colon,
pancreatic, and lung cancer and the emerging finding that gene mutation and
expression profiles in colorectal cancer are associated with tumor location
within the colon and rectum.

Poster Discussion Session
Gene expression profiles and tumor locations in colorectal cancer (left vs.
right vs. rectum)
Date/Time Poster Display: June 4, 2013, 8:00AM – 12:00PM, Location: S405
Date/Time Poster Discussion: June 4, 2013, 11:30AM – 12:30PM, Location: S406

Poster Session
Correlation of ERCC1 mRNA expression with KRAS mutation status in colorectal,
pancreatic, and lung adenocarcinoma
Date/Time: June 3, 2013, 1:15PM – 5:00PM, Location: S Hall A2

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to
the Company's plans, objectives, projections, expectations and intentions,
such as the ability of the Company, to provide clinical testing services to
the medical community, to continue to strengthen and expand its sales force,
to continue to build its digital pathology initiative, to attract and retain
qualified management, to continue to strengthen marketing capabilities, to
expand the suite of ResponseDX® products, to continue to provide clinical
trial support to pharmaceutical clients, to enter into new collaborations with
pharmaceutical clients, to enter into areas of companion diagnostics, to
continue to execute on its business strategy and operations, to continue to
analyze cancer samples and the potential for using the results of this
research to develop diagnostic tests for cancer, the usefulness of genetic
information to tailor treatment to patients, and other statements identified
by words such as "project," "may," "could," "would," "should," "believe,"
"expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission. Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo
 
Press spacebar to pause and continue. Press esc to stop.